TNGXMEDIUM SIGNALFINANCIAL10-K

TNGX significantly strengthened its financial position with a 32% increase in outstanding shares, 73.5% jump in stockholders' equity to $346.2M, and substantial debt reduction of 55.1%.

The company appears to have completed a significant equity raise that funded operations and paid down liabilities, providing a stronger balance sheet foundation. However, the 32% dilution in share count (from 108M to 143M shares) represents meaningful dilution for existing shareholders that investors should carefully evaluate against the improved financial stability.

Comparing 2026-03-05 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

TNGX demonstrated strong overall financial improvement with revenue growing 48.3% to $62.4M and operating losses narrowing by 23.6% to -$111.3M, indicating improving operational efficiency. The balance sheet was substantially strengthened through what appears to be an equity raise, with cash increasing 61.5% to $112.3M, total liabilities declining 55.1%, and stockholders' equity surging 73.5% to $346.2M. While the 32% share dilution is notable, the overall picture suggests TNGX has secured adequate funding to support operations while reducing financial risk through debt paydown.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+73.5%
$199.5M$346.2M

Equity base grew 73.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Cash & Equivalents
Balance Sheet
+61.5%
$69.5M$112.3M

Cash position surged 61.5% — strong cash generation or capital raise providing significant financial cushion.

Total Liabilities
Balance Sheet
-55.1%
$117.0M$52.5M

Liabilities reduced 55.1% — deleveraging improves balance sheet strength and financial flexibility.

Revenue
P&L
+48.3%
$42.1M$62.4M

Strong top-line growth of 48.3% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
-43.2%
$38.2M$21.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Capital Expenditure
Cash Flow
+39%
$754K$1.0M

Capital expenditure jumped 39% — major investment cycle underway; assess returns on deployment.

Current Assets
Balance Sheet
+32.8%
$266.3M$353.8M

Current assets grew 32.8% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+26%
$316.5M$398.7M

Asset base grew 26% — expansion through organic growth, acquisitions, or capital deployment.

Operating Income
P&L
+23.6%
-$145.6M-$111.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+22%
-$130.3M-$101.6M

Net income grew 22% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-02-27
ADDED
As of February 26, 2026, the registrant had 142,688,851 shares of common stock, $0.001 par value per share, outstanding.
Inadequate funding for government agencies in or outside the United States, including from government shutdowns or other disruptions to these agencies' staffing and operations, could prevent new products and services being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.
has the potential to support a chemotherapy-free first line pancreatic cancer pivotal study and potentially second-line therapies in MTAP-deleted/RAS mutated patients; and other risks and uncertainties, including those listed in Part I, Item 1A of this Annual Report on Form 10-K under the section titled Risk Factors.
2025 Annual Report means this Annual Report on Form 10-K for the year ended December 31, 2025; ii.
+7 more — sign up free →
REMOVED
As of February 19, 2025, the registrant had 108,107,890 shares of common stock, $0.001 par value per share, outstanding.
2024 Annual Report means this Annual Report on Form 10-K for the year ended December 31, 2024; ii.
We leverage our state-of-the-art target discovery platform to identify novel targets and develop new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need.
Tumor suppressor gene loss remains a largely unaddressed target space specifically because these genetic events cannot be directly targeted.
We also are extending this target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss to include the discovery of novel targets that reverse tumor suppressor gene mediated immune evasion which prevents the immune system from recognizing and killing cancer cells.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →